- Home
- TILE vs MNKD Comparison
TILE vs MNKD Comparison
Compare TILE & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- MNKD
- Stock Information
- Founded
- TILE 1973
- MNKD 1991
- Country
- TILE United States
- MNKD United States
- Employees
- TILE N/A
- MNKD N/A
- Industry
- TILE Home Furnishings
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- MNKD Health Care
- Exchange
- TILE Nasdaq
- MNKD Nasdaq
- Market Cap
- TILE 1.2B
- MNKD 1.1B
- IPO Year
- TILE N/A
- MNKD 2004
- Fundamental
- Price
- TILE $20.74
- MNKD $3.80
- Analyst Decision
- TILE Buy
- MNKD Strong Buy
- Analyst Count
- TILE 1
- MNKD 5
- Target Price
- TILE $30.00
- MNKD $9.60
- AVG Volume (30 Days)
- TILE 331.6K
- MNKD 3.3M
- Earning Date
- TILE 08-01-2025
- MNKD 08-06-2025
- Dividend Yield
- TILE 0.19%
- MNKD N/A
- EPS Growth
- TILE 44.62
- MNKD 228.27
- EPS
- TILE 1.46
- MNKD 0.10
- Revenue
- TILE $1,323,328,000.00
- MNKD $297,595,000.00
- Revenue This Year
- TILE $5.19
- MNKD $13.72
- Revenue Next Year
- TILE $4.91
- MNKD $14.94
- P/E Ratio
- TILE $14.46
- MNKD $36.40
- Revenue Growth
- TILE 5.41
- MNKD 32.50
- 52 Week Low
- TILE $14.75
- MNKD $3.51
- 52 Week High
- TILE $27.34
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- TILE 51.06
- MNKD 47.98
- Support Level
- TILE $20.54
- MNKD $3.73
- Resistance Level
- TILE $21.60
- MNKD $4.05
- Average True Range (ATR)
- TILE 0.61
- MNKD 0.14
- MACD
- TILE -0.10
- MNKD 0.05
- Stochastic Oscillator
- TILE 30.20
- MNKD 60.19
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.